Galimedix Therapeutics completed the single ascending dose part of a phase 1 study of GAL-101, a potential oral therapy under ...

In the retina, age-related macular degeneration (AMD ... proteins, cellular debris, amyloid deposits, apolipoproteins, iron and zinc ions, and contribute to the development and progression ...

For the three months ended March 31, 2025, the Company reported a net loss of $2.12 million, compared to a net loss of $1.72 million in the same period the previous year. The increase was largely ...

Your eyes and brain aren't just close together-they're connected. Simply put, your retina and optic nerve are extensions of ...

Alzheimer’s disease stands as the most widespread form of dementia globally, increasingly burdening families, healthcare systems, and societies as populations age. Although current treatments, ...

Galimedix’s groundbreaking small molecules offer the hope of changing the course of disease where amyloid beta (Aβ) plays a role, such as in dry age-related macular degeneration (AMD), glaucoma and ...

The CHMP also adopted a positive opinion for Attrogy (diflunisal) for the treatment of hereditary TTR–mediated amyloidosis in adult patients with stage I or stage II polyneuropathy. The ...

Medications like lecanemab (Leqembi) and donanemab (Kisunla) target amyloid plaques in the brain that build up due to Alzheimer’s disease. They may help slow disease progression for people in ...

Vutrisiran is currently approved in the European Union (EU) under the brand name AMVUTTRA ® for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage ...

Alnylam has been a pioneer in hereditary ATTR amyloidosis, getting approval in 2018 for the first drug to treat the rare disease, and has now launched a digital companion to help patients track ...

Australian reporter Iain Finlay has died by euthanasia after a lengthy battle with a rare disease called amyloidosis. He was 89. Finlay, a former journalist for the Australian Broadcasting ...